NCT04452669View on ClinicalTrials.gov

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions
COVID-19
Interventions
DRUG

VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)

VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.

Trial Locations (1)

43210

Ohio State University, Columbus

Sponsors
All Listed Sponsors
collaborator

Ohio State University

OTHER

lead

Aerogen Pharma Limited

INDUSTRY